Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Peregrine Ventures

Investor type Incubator
Founders Boaz Lifschitz Eyal Lifschitz


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 85
Average round size
The average size of a deal this fund participated in
Portfolio companies 58
Rounds per year 3.86
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 11
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Medical Device
  • Biotechnology
  • Software
  • Medical

Peregrine Ventures appeared to be the VC, which was created in 2001. The main department of described VC is located in the Or Yehuda. The company was established in Asia in Israel.

This organization was formed by Boaz Lifschitz, Eyal Lifschitz. We also calculated 3 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Peregrine Ventures, startups are often financed by Accelmed, Elron Electronic Industries, Access Medical Ventures. The meaningful sponsors for the fund in investment in the same round are Pitango Venture Capital, Johnson & Johnson Innovation, Elron Electronic Industries. In the next rounds fund is usually obtained by Three Arch Partners, Pitango Venture Capital, ONSET Ventures.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Social Media Marketing, Network Security. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. Among the most popular portfolio startups of the fund, we may highlight CartiHeal, VisionCare Ophthalmic Technologies, Kailight Photonics.

The real fund results show that this VC is 10 percentage points less often commits exit comparing to other companies. Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The top amount of exits for fund were in 2016. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Peregrine Ventures works on 9 percentage points less the average amount of lead investments.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Peregrine Ventures:
Typical Co-investors
Peregrine Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Peregrine Ventures:

Funds with similar focus

Funds from Israel
Funds with similar focus located in Israel:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Bespoke Strategies -
Bluepoint Partners Daejeon, South Korea, Taejon-jikhalsi
Dendera Ventures -
GitHub California, San Francisco, United States
Gogreen Capital Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Hangzhou Mien Touzi Hehuo Qiye (Youxian Hehuo) China, Hangzhou, Zhejiang
Huaqiang Asset Management Group China, Guangdong, Shenzhen
Insignia Capital Group California, United States, Walnut Creek
Lionsgate California, Santa Monica, United States
Mohamad Moosa Abdulrahman Investment -
NEWTIMING China, Hangzhou, Zhejiang
Octane Venture Partners Alberta, Calgary, Canada
Planet A Ventures Germany, Hamburg
Rare Ventures New York, New York, United States
Softline Venture Partners Moscow, Moscow, Russia
Stage 1 Ventures Massachusetts, United States, Waltham
Steigen -
Turner Investments Berwyn, Pennsylvania, United States
ustwo England, London, United Kingdom

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

DataMesh Group

IT Infrastructure
$21M21 Feb 2023 -

Nectin Therapeutics

Life Science
$25M30 Nov 2022 Jerusalem, Jerusalem District, Israel

CORDIO Medical

$18M27 Jun 2022 Israel, Tel Aviv District, Israel


Health Care
Health Diagnostics
Information Technology
Life Science
Personal Health
$41M14 Feb 2022 Framingham, Massachusetts, United States

Blue White Robotics

Autonomous Vehicles
$37M23 Sep 2021 Tel Aviv-Yafo, Tel Aviv District, Israel


Medical Device
$40M16 Aug 2021 Jerusalem, Jerusalem District, Israel

Aleph Farms

Food and Beverage
Green Consumer Goods
$105M07 Jul 2021 Rishon Lezion, Center District, Israel

KAHR medical

$46M16 Jun 2021 Jerusalem, Jerusalem District, Israel

Ribon Therapeutics

Health Care
Medical Device
$65M14 Jun 2021 Massachusetts, United States
Breakthrough Israeli stroke therapy technology BrainQ announces a $40M funding round

– Israeli stroke therapy technology startup, BrainQ, today announced a $40m funding round led by Hanaco Ventures, along with Dexcel Pharma, and Peregrine Ventures.
– The funding will be used to support a multicenter pivotal trial for its groundbreaking technology for ischemic stroke survivors in selected US hospitals.
– This year, BrainQ received FDA Breakthrough Device Designation allowing the company to work closely with the FDA to expedite development plans and premarket clearance, with access to the new Medicare Coverage of Innovative Technology pathway.

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Peregrine Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: